Vigil Neuroscience, Inc. (VIGL)
$3.87
Live
Performance
- $3.82$3.99$3.87
1.29%
Downside
Day's Volatility :4.26%
Upside
3.01%
- $2.47$9.24$3.87
36.18%
Downside
52 Weeks Volatility :73.27%
Upside
58.12%
Returns
| Period | Vigil Neuroscience, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 1.28% | 3.6% | 0.0% |
6 Months | 39.44% | 10.2% | 0.0% |
1 Year | -47.62% | 19.6% | 0.0% |
3 Years | -68.7% | 16.8% | -23.0% |
Highlights
Market Capitalization | 163.5M |
Book Value | $2.27 |
Earnings Per Share (EPS) | -2.11 |
Wall Street Target Price | 15.88 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -39.66% |
Return On Equity TTM | -70.12% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -89.6M |
Diluted Eps TTM | -2.11 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.13 |
EPS Estimate Next Year | -2.03 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.46 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 310.34%
Technicals Summary
Sell
Neutral
Buy
Vigil Neuroscience, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Vigil Neuroscience, Inc. | 27.33% | 39.44% | -47.62% | -68.7% | -68.7% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Vigil Neuroscience, Inc. | NA | NA | NA | -2.13 | -0.7 | -0.4 | NA | 2.27 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Vigil Neuroscience, Inc. | Buy | $163.5M | -68.7% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Vigil Neuroscience, Inc.
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 129.5%
Institutional Holdings
Northpond Ventures, LLC
10.63%Artal Group S A
4.61%Bvf Inc
4.57%Sphera Funds Management Ltd.
4.27%Point72 Asset Management, L.P.
3.75%Citadel Advisors Llc
3.64%
Company Information
vigil neuroscience is the world’s first microglia-focused therapeutics company. our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. we are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
Organization | Vigil Neuroscience, Inc. |
Employees | 64 |
CEO | Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. |
Industry | Services |
